0001415889-23-002162.txt : 20230208 0001415889-23-002162.hdr.sgml : 20230208 20230208163640 ACCESSION NUMBER: 0001415889-23-002162 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230206 FILED AS OF DATE: 20230208 DATE AS OF CHANGE: 20230208 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ezickson Elan CENTRAL INDEX KEY: 0001486429 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36576 FILM NUMBER: 23599655 MAIL ADDRESS: STREET 1: AVEO PHARMACEUTICALS, INC. STREET 2: 75 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MARINUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001267813 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5 RADNOR CORPORATE CENTER SUITE 500 STREET 2: 100 MATSONFORD RD CITY: RADNOR STATE: PA ZIP: 19087 BUSINESS PHONE: 484-801-4670 MAIL ADDRESS: STREET 1: 5 RADNOR CORPORATE CENTER SUITE 500 STREET 2: 100 MATSONFORD RD CITY: RADNOR STATE: PA ZIP: 19087 FORMER COMPANY: FORMER CONFORMED NAME: MARINUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20031022 4 1 form4-02082023_090232.xml X0306 4 2023-02-06 0001267813 MARINUS PHARMACEUTICALS, INC. MRNS 0001486429 Ezickson Elan 5 RADNOR CORPORATE CENTER, SUITE 500 100 MATSONFORD RD RADNOR PA 19087 true false false false Common Stock 2023-02-06 4 S 0 750 6.56 D 5600 D The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the "Company") sold by the reporting person pursuant to a Rule 10b5-1 plan to cover tax obligations in connection with the vesting of previously granted restricted stock units. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $6.55 - $6.56, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. /s/ Debra A. Mohollen, Attorney-in-Fact 2023-02-08